Keros Therapeutics (KROS) Financials: History & Chart

Keros Therapeutics, Inc.(KROS)

Biotechnology · Lexington, MA

$11.01-0.51 (-4.43%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Lexington, MA

92 employees

www.kerostx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jasbir S. Seehra

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	15.01M	0.00	367K	385K	14.26M	18.17M	211.25M	3.04M	388K
Cost of Goods Sold	798K	0.00	403K	0.00	395K	370K	0.00	332K	314K
Gross Profit	14.22M	0.00	-36K	385K	13.87M	17.80M	211.25M	2.71M	74K
Gross Profit Margin	94.7%	N/A	-9.8%	100.0%	97.2%	98.0%	100.0%	89.1%	19.1%
Total Operating Expenses	115.68M	30.94M	25.84M	29.66M	29.25M	57.62M	59.21M	55.96M	58.73M
Research & Development	75.86M	22.33M	16.10M	17.91M	19.52M	43.50M	48.71M	45.63M	49.23M
Selling, General & Administrative	40.62M	8.61M	10.15M	11.74M	10.13M	14.48M	10.50M	10.66M	9.82M
Operating Income (EBIT)	-101.47M	-30.94M	-25.88M	-29.27M	-15.38M	-39.82M	152.04M	-53.25M	-58.66M
Operating Margin	-675.8%	N/A	-7051.0%	-7602.6%	-107.9%	-219.2%	72.0%	-1750.6%	-15117.8%
Income Before Tax (EBT)	-86.10M	-28.71M	-23.71M	-24.98M	-8.70M	-32.92M	158.49M	-45.73M	-52.96M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	15.37M	2.23M	2.17M	4.29M	6.68M	6.90M	6.45M	7.53M	5.70M
Net Income	-83.16M	-28.71M	-23.71M	-23.46M	-7.28M	-30.70M	148.45M	-46.03M	-52.96M
Income Tax Expense	-2.94M	0.00	0.00	-1.51M	-1.42M	-2.22M	10.04M	300K	0.00
Net Profit Margin	-553.9%	N/A	-6459.9%	-6093.8%	-51.0%	-169.0%	70.3%	-1513.0%	-13648.5%
EBITDA	-99.87M	-30.54M	-25.47M	-28.87M	-14.99M	-39.45M	152.38M	-52.92M	-58.34M
EBITDA Margin	-665.2%	N/A	-6941.1%	-7498.7%	-105.1%	-217.1%	72.1%	-1739.7%	-15036.9%
Depreciation & Amortization	1.60M	402K	403K	400K	395K	370K	344K	332K	314K
EPS Basic	-3.70	-1.45	-1.21	-0.86	-0.18	-0.76	3.66	-1.14	-1.47
EPS Diluted	-3.22	-1.45	-1.21	-0.38	-0.18	-0.76	3.62	-1.14	-1.47
Weighted Average Basic Shares	19.80M	19.80M	19.63M	27.20M	40.62M	40.61M	40.56M	40.34M	36.10M
Weighted Average Diluted Shares	19.80M	19.80M	19.63M	27.20M	40.62M	40.61M	41.02M	40.34M	36.10M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	244.06M	3.55M	151K	0.00	20.10M	0.00	10.00M	10.00M
Cost of Goods Sold	1.51M	0.00	0.00	0.00	0.00	605K	17.35M	10.11M
Gross Profit	242.55M	3.55M	151K	0.00	20.10M	-605K	-7.35M	-111K
Gross Profit Margin	99.4%	100.0%	100.0%	N/A	100.0%	N/A	-73.5%	-1.1%
Total Operating Expenses	171.93M	214.38M	170.09M	114.79M	76.47M	46.05M	20.00M	11.32M
Research & Development	129.64M	173.63M	135.26M	87.27M	55.14M	33.86M	17.38M	10.11M
Selling, General & Administrative	46.85M	40.75M	34.83M	27.52M	21.33M	12.19M	3.18M	1.58M
Operating Income (EBIT)	70.62M	-210.83M	-169.94M	-114.79M	-56.37M	-46.66M	-10.56M	-1.69M
Operating Margin	28.9%	-5939.0%	-112543.7%	N/A	-280.5%	N/A	-105.6%	-16.9%
Income Before Tax (EBT)	91.90M	-187.05M	-152.99M	-104.68M	-56.73M	-45.53M	-12.34M	-1.08M
Interest Income	N/A	N/A	N/A	1K	N/A	6K	N/A	6K
Interest Expense	N/A	N/A	N/A	1K	4K	6K	8K	N/A
Other Income/Expense	21.27M	23.78M	16.95M	10.11M	-360K	1.12M	-1.77M	613K
Net Income	87.01M	-187.35M	-152.99M	-104.68M	-58.74M	-45.36M	-12.34M	-1.33M
Income Tax Expense	4.88M	300K	0.00	0.00	2.01M	-172K	0.00	257K
Net Profit Margin	35.7%	-5277.5%	-101319.2%	N/A	-292.3%	N/A	-123.4%	-13.4%
EBITDA	72.13M	-209.60M	-169.13M	-114.12M	-55.99M	-46.05M	-10.13M	-1.39M
EBITDA Margin	29.6%	-5904.3%	-112004.0%	N/A	-278.6%	N/A	-101.3%	-13.9%
Depreciation & Amortization	1.51M	1.23M	815K	674K	378K	605K	438K	304K
EPS Basic	2.34	-5.00	-5.20	-4.15	-2.52	-2.93	-1.39	-0.15
EPS Diluted	2.30	-5.00	-5.20	-4.15	-2.52	-2.93	-1.39	-0.15
Weighted Average Basic Shares	37.22M	37.44M	29.45M	25.24M	23.33M	15.51M	8.88M	8.88M
Weighted Average Diluted Shares	37.86M	37.44M	29.45M	25.24M	23.33M	15.51M	8.88M	8.88M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.